Video

Dr. Biran on New Agents and Combos in Relapsed Multiple Myeloma

Author(s):

Noa Biran, MD, discusses new agents and combinations being studied for relapsed multiple myeloma.

Noa Biran, MD, physician, John Theurer Cancer Center, discusses new agents and combinations being studied for relapsed multiple myeloma.

Many large phase III trials have shown improvement in patients with relapsed multiple myeloma in terms of progression-free survival (PFS) or overall survival, according to Biran. Isatuximab, a monoclonal antibody to CD38, has been shown in a large randomized phase III study in combination with pomalidomide (Pomalyst) and dexamethasone to significantly improve overall response rate and PFS compared with pomalidomide and dexamethasone alone in patients with ≥2 prior lines of therapy. Due to these results, Biran predicts isatuximab will soon be on the market as another monoclonal antibody.

In early-stage trials, researchers are studying iberdomide (CC-220), an oral agent that’s showing in combination with dexamethasone to have significant activity in patients with heavily pretreated disease. Additionally, the anti-BCMA bi-specific T-cell engager antibody construct AMG 420 is showing significant activity, even as a single agent.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies
Audio

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Jun 18th 2025 - Jun 19th 2026

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity